Botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti-PD-1) in patients with recurrent platinum refractory/resistant ovarian cancer (041)
Year: 2023
Type: article
Study design: Clinical Trial
Source: Gynecologic Oncology
Authors: Bruno Bockorny, Ursula Matulonis, Steven O'Day, Kim Margolin, Anthony El-Khoueiry, Breelyn Wilky, Rachel Sanborn, Ani Balmanoukian, Andrea Bullock, Gerburg Wulf, Timothy Kristedja, Diana Hanna, Joseph Grossman, Waldo Ortuzar Feliu, Katherine Rosenthal, James Godwin, Jaymin Patel, Brandon Beagle, Bonnie Bullock, Bhupendra Rawal, Hunter Cole, Xin (James) Song, Daruka Mahadevan, Michael Gordon
Institutions: Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Agenus (United States), Saint John's Health Center, USC Norris Comprehensive Cancer Center, University of Colorado Cancer Center, Providence Portland Medical Center, Angeles Clinic and Research Institute, The University of Texas at San Antonio Health Science Center, HonorHealth
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4386948493